1. Home
  2. STKS vs IMUX Comparison

STKS vs IMUX Comparison

Compare STKS & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo The ONE Group Hospitality Inc.

STKS

The ONE Group Hospitality Inc.

HOLD

Current Price

$1.74

Market Cap

55.6M

ML Signal

HOLD

Logo Immunic Inc.

IMUX

Immunic Inc.

HOLD

Current Price

$1.18

Market Cap

152.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
STKS
IMUX
Founded
2004
2016
Country
United States
United States
Employees
N/A
66
Industry
Restaurants
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
55.6M
152.6M
IPO Year
2011
2013

Fundamental Metrics

Financial Performance
Metric
STKS
IMUX
Price
$1.74
$1.18
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
5
Target Price
$4.70
$4.80
AVG Volume (30 Days)
46.4K
1.8M
Earning Date
05-06-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
38.00
EPS
N/A
N/A
Revenue
$805,722,000.00
N/A
Revenue This Year
$8.50
N/A
Revenue Next Year
$9.02
N/A
P/E Ratio
N/A
N/A
Revenue Growth
19.66
N/A
52 Week Low
$1.66
$0.51
52 Week High
$5.19
$1.51

Technical Indicators

Market Signals
Indicator
STKS
IMUX
Relative Strength Index (RSI) 45.33 53.23
Support Level $1.67 $1.05
Resistance Level $2.03 $1.35
Average True Range (ATR) 0.12 0.11
MACD 0.00 -0.01
Stochastic Oscillator 21.62 53.13

Price Performance

Historical Comparison
STKS
IMUX

About STKS The ONE Group Hospitality Inc.

The One Group Hospitality Inc is a restaurant company that develops, owns and operates, manages and licenses upscale and polished casual, high-energy restaurants and lounges and provides turn-key food and beverage (F&B) services for hospitality venues, including hotels, casinos, and other high-end locations internationally. The company operates through three segments: STK, Benihana and Grill Concepts. The company generates the vast majority of its revenue from the domestic market.

About IMUX Immunic Inc.

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.

Share on Social Networks: